Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxytocin intranasal - Vyera Pharmaceuticals

X
Drug Profile

Oxytocin intranasal - Vyera Pharmaceuticals

Alternative Names: Syntocinon Nasal Spray; TUR 001

Latest Information Update: 04 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Developer Retrophin; Turing Pharmaceuticals; University of California, San Diego
  • Class Amides; Amines; Analgesics; Antihaemorrhagics; Antihyperglycaemics; Antimigraines; Behavioural disorder therapies; Hormones; Macrocyclic lactams; Obesity therapies; Oxytocics; Pyrrolidines
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Autistic disorder; Lactation failure; Schizophrenia

Most Recent Events

  • 17 Aug 2018 University of North Carolina at Chapel Hill plans the phase II OT-ETOH-4 trial for Alcoholism (In adults, In the elderly) in USA (Intranasal) (NCT03636555)
  • 01 Sep 2017 Turing Pharmaceuticals is now called Vyera Pharmaceuticals (Vyera Pharmaceuticals California Comprehensive Compliance Program, September 2017)
  • 15 Feb 2017 Discontinued - Clinical-Phase-Unknown for Schizophrenia (Adjunctive treatment) in USA (Intranasal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top